Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

World Journal of Gastroenterology

Volumn 16, Issue 45, 2010, Pages 5651-5661

  Bessone, Fernando ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Cholestasis; Fulminant hepatic failure; Hepatitis; Hepatotoxicity; Liver damage; Liver injury; Non steroidal anti inflammatory drugs; Side effects

Indexed keywords

BENOXAPROFEN; BROMFENAC; IBUFENAC; NONSTEROID ANTIINFLAMMATORY AGENT;

DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDITORIAL; HOSPITALIZATION; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; RISK FACTOR;

EID: 78649844430     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i45.5651     Document Type: Editorial

References (97)

1. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
2. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32: 3-13
3. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007; 6: 673-684
4. Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sørensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Køber L, Torp-Pedersen C. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther 2009; 85: 190-197
5. Drug Safety Update. Volume 2, Issue 7, February 2009
6. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006; 15: 213-220
7. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 563-575, vi-vii
8. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48: 1680-1689
9. Reuben A, Koch DG, Lee WM. Acute liver failure secondary to drug induced liver injury: causes and consequences (Abstract). Hepatology 2009; 50 Suppl: 347A
10. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485
11. Rabkin JM, Smith MJ, Orloff SL, Corless CL, Stenzel P, Olyaei AJ. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999; 33: 945-947
12. Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol 1999; 94: 2299-2301
13. EMEA: European Medicines Agency. European Medicines Agency recommends restricted use of nimesulide-containing medicinal products (on-line). Available from: URL: http://www.emea.europa.eu/pdfs/general/direct/pr/43260407en.pdf
14. ANMAT Administración Nacional de Medicamentos Alimentos y Tecnología Medica Disposición 4087/03 (on-line). Argentina Acceso: 15/08/2009. Available from: URL: http://www.anmat.gov.ar
15. Nota informativa de la Agencia Española del Medicamento sobre Nimesulida. 2002. Available from: URL: http://www.osanet.euskadi.net/contenidos/informacion/notas_seg_cevime/eu_1676/adjuntos/02-05-06nimesulida.pdf
16. WHO Pharmaceuticals Newsletter 2002, No. 04. Available from: URL: http://apps.who.int/medicinedocs/fr/d/Js4943e/3.1.html
17. García Rodríguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 1994; 154: 311-316
18. Pérez Gutthann S, García Rodríguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4: 496-501
19. Licata A, Calvaruso V, Cappello M, Craxì A, Almasio PL. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis 2010; 42: 143-148
20. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009; 58: 1555-1564
21. Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489-498
22. García Rodríguez LA, Pérez Gutthann S, Walker AM, Lueck L. The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 1992; 305: 865-868
23. Traversa G, Bianchi C, Da Cas R, Abraha I, Menniti-Ippolito F, Venegoni M. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18-22
24. de Abajo FJ, Montero D, Madurga M, Garcãa Rodrãguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80
25. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009; 104: 356-362
26. Rubenstein JH, Laine L. Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 373-380
27. FDA Working Group. PhRMA/FDA/AASLD. Drug-induced hepatotoxicity: white paper, postmarketing considerations. PhRMA/FDA/AASLD: 2000; 1-29. Accessed October 29, 2008. Available from: URL: http://www.fda.gov/cder/livertox/postmarket.pdf
28. FDA Working Group. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), July 2009
29. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3-27
30. Zimmerman HJ. Editorial: Aspirin-induced hepatic injury. Ann Intern Med 1974; 80: 103-105
31. Russell AS, Sturge RA, Smith MA. Serum transaminases during salicylate therapy. Br Med J 1971; 2: 428-429
32. Rainsford KD. Side-effects and toxicology of the salicylates. In: Rainsford KD, ed. Aspirin and Related Drugs. Boca Raton, Florida: CRC Press, 2004: 367-554
33. Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003; 7: 401-413
34. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981; 141: 333-342
35. Doi H, Horie T. Salicylic acid-induced hepatotoxicity triggered by oxidative stress. Chem Biol Interact 2010; 183: 363-368
36. Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006; 152: 237-245
37. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368: 1771-1781
38. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820-827
39. Jick H, Derby LE, García Rodríguez LA, Jick SS, Dean AD. Liver disease associated with diclofenac, naproxen, and piroxicam. Pharmacotherapy 1992; 12: 207-212
40. Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Zala GF, Flury R, Seelentag W, Roth J, Meyenberger C, Fried M, Hoppeler T, Spigelman AD, Scott RJ. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis. Dis Colon Rectum 2001; 44: 1090-1097; discussion 1097-1099
41. Tarazi EM, Harter JG, Zimmerman HJ, Ishak KG, Eaton RA. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993; 104: 569-574
42. Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci 2009; 108: 184-193
43. Zou W, Beggs KM, Sparkenbaugh EM, Jones AD, Younis HS, Roth RA, Ganey PE. Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther 2009; 331: 114-121
44. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 17: 275-342
45. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996; 91: 1626-1630
46. Laurent S, Rahier J, Geubel AP, Lerut J, Horsmans Y. Subfulminant hepatitis requiring liver transplantation following ibuprofen overdose. Liver 2000; 20: 93-94
47. Riley TR 3rd, Smith JP. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series. Am J Gastroenterol 1998; 93: 1563-1565
48. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis 2004; 63: 1028-1034
49. Doyle G, Furey S, Berlin R, Cooper S, Jayawardena S, Ashraf E, Baird L. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999; 13: 897-906
50. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA. The safety profile of nonprescription ibuprofen in multiple-dose use: a meta-analysis. J Clin Pharmacol 1999; 39: 520-532
51. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528, 2 p following 1528
52. Bessone F. Non-steroidal anti-inflammatory drugs do not protect against coronary heart disease among people at high risk. Evid base Cardiovasc Med 2002; 6: 62
53. Rainsford KD. Introduction - The coxib controversies. Inflammopharmacology 2005; 13: 331-341
54. FDA Requests Voluntarily Withdrawal of Valdecoxib (Bextra®) from US Markets. Available from: URL: http://google2.fda.gov/search?q=cox+2&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=*&x=17&y=14
55. Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008; 38: 165-187
56. Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002; 25: 633-648
57. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255
58. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-674
59. Medicines and Healthcare products Regulatory Authority. Lumiracoxib (Prexige): suspension of marketing authorisation. 2007. Accessed January 25, 2008. Available from: URL: http://www.mhra.gov.uk/onlineservices/medicines/druganalysisprints/index.htm
60. Techman A. Novartis Withdraws Lumiracoxib (Prexige®) in Australia in Response to Decision From Therapeutic Goods Administration to Cancel Registration. CIAOMed. August 14, 2007. Available from: URL: http://www.mskreports.com/search_results.cfm?searchterm=cox-2
61. Yan B, Leung Y, Urbanski SJ, Myers RP. Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs. Can J Gastroenterol 2006; 20: 351-355
62. Huster D, Schubert C, Berr F, Mössner J, Caca K. Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J Hepatol 2002; 37: 413-414
63. Papachristou GI, Demetris AJ, Rabinovitz M. Acute cholestatic hepatitis associated with long-term use of rofecoxib. Dig Dis Sci 2004; 49: 459-461
64. Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007; 34: 408-420
65. Kang P, Dalvie D, Smith E, Renner M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts. Chem Res Toxicol 2009; 22: 106-117
66. Souto EO, Miyoshi H, Dubois RN, Gores GJ. Kupffer cell-derived cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G805-G811
67. Farrell GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994
68. Lee SM, O'Brien CJ, Williams R, Whitaker S, Gould SR. Subacute hepatic necrosis induced by piroxicam. Br Med J (Clin Res Ed) 1986; 293: 540-541
69. Planas R, De León R, Quer JC, Barranco C, Bruguera M, Gassull MA. Fatal submassive necrosis of the liver associated with piroxicam. Am J Gastroenterol 1990; 85: 468-470
70. Paterson D, Kerlin P, Walker N, Lynch S, Strong R. Piroxicam induced submassive necrosis of the liver. Gut 1992; 33: 1436-1438
71. Poniachik J, Guerrero J, Calderón P, Smok G, Morales A, Muñoz G, Venegas M. [Cholestatic hepatitis associated with piroxicam use. Case report] Rev Med Chil 1998; 126: 548-552
72. Hepps KS, Maliha GM, Estrada R, Goodgame RW. Severe cholestatic jaundice associated with piroxicam. Gastroenterology 1991; 101: 1737-1740
73. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-183
74. Caballeria E, Masso RM, Arago JV, Sanchis A. Piroxicam hepatotoxicity. Am J Gastroenterol 1990; 85: 898-899
75. Bennett A. Nimesulide: a well-established cyclo-oxygenase-2inhibitor with many other pharmacological properties relevantto inflammatory disease. In: Vane JR, Botting RM, eds. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press, 2001: 524-540
76. Bessone F, Fay F, Vorobioff J, Passamonti ME, Godoy A, Tanno H. Nimesulide hepatotoxicity: Evidence from six cases. Hepatology 1997; 26: 483A
77. Grignola JC, Arias L, Rondan M, Sola L, Bagnulo H. Hepatoxicity associated to nimesulide [Revision of five cases]. Arch Med Int 1998; 20: 13-18
78. Selig J, Liberek C, Kondo Oestreicher M, Desmeules J, Stoller R. Nimesulide hepatotoxicity. Poster presented at the 6th Annual Meeting of the European Society of Pharmacovigilance - Budapest, September 28-29, 1998
79. Romero Gómez M, Nevado Santos M, Fobelo MJ, Castro Fernández M. [Nimesulide acute hepatitis: description of 3 cases] Med Clin (Barc) 1999; 113: 357-358
80. Ozgür O, Hacihasanoǧlu A, Karti SS, Ovali E. Nimesulide-induced fulminant hepatitis. Turk J Gastroenterol 2003; 14: 208-210
81. Lewin S. Post-marketing surveillance of nimesulide suspension. Indian Pediatr 2002; 39: 890-891; author reply 891-892
82. Andrade RJ, Lucena MI, Fernández MC, González M. Fatal hepatitis associated with nimesulide. J Hepatol 2000; 32: 174
83. Pérez-Moreno J, Llerena Guerrero RM, Puertas Montenegro M, Jiménez Arjona MJ. [Nimesulide toxic hepatitis in pregnancy] Gastroenterol Hepatol 2000; 23: 498-499
84. Papaioannides D, Korantzopoulos P, Athanassiou E, Sinapidis D. Nimesulide-induced acute hepatotoxicity. Indian J Gastroenterol 2003; 22: 239
85. Tejos S, Torrejón N, Reyes H, Meneses M. [Bleeding gastric ulcers and acute hepatitis: 2 simultaneous adverse reactions due to nimesulide in a case] Rev Med Chil 2000; 128: 1349-1353
86. Dourakis SP, Sevastianos VA, Petraki K, Hadziyannis SJ. Nimesulide induced acute icteric hepatitis. Iatriki 2001; 79: 275-278
87. Rodrigo L, de Francisco R, Pérez-Pariente JM, Cadahia V, Tojo R, Rodriguez M, Lucena MI, Andrade RJ. Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation. Scand J Gastroenterol 2002; 37: 1341-1343
88. Stadlmann S, Zoller H, Vogel W, Offner FA. COX-2 inhibitor (nimesulide) induced acute liver failure. Virchows Arch 2002; 440: 553-555
89. Polimeni G, Salvo F, Cutroneo P, Morreale I, Patrizio Caputi A. Adverse reactions induced by NSAIDs and antibacterials: analysis of spontaneous reports from the Sicilian regional database. Drug Saf 2006; 29: 449-459
90. Maciá MA, Carvajal A, del Pozo JG, Vera E, del Pino A. Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System. Clin Pharmacol Ther 2002; 72: 596-597
91. Press Release: European Medicines Evaluation Agency (EMEA) states that nimesulide is safe and effective. 2003. Accessed September 16, 2004. Available from: URL: http://www.mahalo.com/nimesulide
92. Conforti A, Leone R, Moretti U, Mozzo F, Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 1081-1090
93. Bessone F, Colombato L, Pasamonti ME, Godoy A, Vorobioff J, Tanno H. Nimesulide: clinical and histological evidences of severe hepatotoxicity. J Hepatol 2001; 34 (Suppl 1): 46
94. Bessone F, Colombato L, Fassio E, Reggiardo MV, Vorobioff J, Tanno H. The spectrum of nimesulide-induced-hepatotoxicity. An overview. Anti-Inflamm & Anti-Allergy Agents Med Chem 2010; 9: 355-365
95. Bessone F, Tanno H. [Hepatotoxicity induced by non-steroidal anti-inflammatory drugs] Gastroenterol Hepatol 2000; 23: 200-205
96. Walker SL, Kennedy F, Niamh N, McCormick PA. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf 2008; 17: 1108-1112
97. Bjarnason I, Bissoli F, Conforti A, Maiden L, Moore N, Moretti U, Rainsford KD, Takeuchi K, Velo GP. Adverse reactions and their mechanisms from nimesulide. In: Rainsford KD, ed. Nimesulide - Actions and Uses. Basel Switzerland: Birkhäuser Verlag, 2005: 315-341